Methods of administering camptothecin compounds for the treatment of cancer with reduced side effects

• US 6,635,628 B2
• Filed: 06/17/2002
• Issued: 10/21/2003
• Est. Priority Date: 06/18/1998
• Status: Expired due to Fees

• Current Assignee: George Washington University
• Original Assignee: George Washington University
• Inventors: Kobayashi, Kunihiko, Bouscarel, Bernard
• Primary Examiner(s): Goldberg, Jerome D.
• Application Number:
  US10/171,691
• Publication Number:
  US 20020193391A1
• Time in Patent Office: 491 Days
• Field of Search: 514/171
• US Class Current: 514/171
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/47 Quinolines; Isoquinolines
• CPC Class Codes: A61K 31/4745 condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 31/706 containing six-membered rings with nitrogen as a ring hetero atom
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: A61K 33/10 Carbonates; Bicarbonates
• CPC Class Codes: A61K 47/02 Inorganic compounds
• CPC Class Codes: A61K 47/12 Carboxylic acids; Salts or anhydrides thereof
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/1075 Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers A61K9/0026 takes precedence

Abstract

Methods of administering camptothecin compounds such as irinotecan hydrochloride to reduce a diarrhea side effect and methods of treating cancer and AIDs with camptothecin compounds including administering the camptothecin compounds while maintaining the intestinal lumen and the bile at an alkaline pH.

Claims

1. A method of inhibiting a diarrhea side effect in a patient receiving a treatment with a camptothecin compound, the method comprising:

administering a camptothecin compound selected from the group consisting of irinotecan hydrochloride CPT-11-Glu, SN-38-Glu, SN-38, 10,11-methylenedioxy-20(RS)-camptothecin, 9-amino-20(RS)-camptothecin and 7-hydroxy-methyl camptothecin in the amount of 10 mg/m² to 700 mg/m² to a patient in need thereof while maintaining the intestinal lumen of the patient at an alkaline pH of 7 to 10 by administering urso-deoxycholic acid to the patient to stimulate bicarbonate secretion into bile of the patient.